Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
17 janv. 2025 05h21 HE
|
Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
Amplify ETFs Achieves Landmark $10 Billion in Assets Under Management
16 janv. 2025 07h00 HE
|
Amplify ETFs
Amplify ETFs surpassed $10 billion in assets under management in its eight-year journey as an ETF sponsor.
Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care
15 janv. 2025 08h05 HE
|
Amwell
Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care.
Noom’s GLP-1 Companion Receives Major Update to Prepare for New Expected Prescription Drug Use-Related Software (PDURS) Model
14 janv. 2025 08h02 HE
|
Noom Inc
Noom announces a major update of its GLP-1 Companion program, unveiling new tools and content designed to enhance and optimize GLP-1 wellness journeys.
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 janv. 2025 09h00 HE
|
Biomea Fusion, Inc.
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
13 janv. 2025 08h00 HE
|
Kailera Therapeutics, Inc.
Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
10 janv. 2025 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024
09 janv. 2025 09h00 HE
|
Guidepoint Qsight
GLP-1 medications drove 13% of non-surgical aesthetic spend in 2024, reshaping the $19.2B industry as medspas see rising revenue and younger patients.
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
08 janv. 2025 08h05 HE
|
Kailera Therapeutics, Inc.
Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h15 HE
|
Kailera Therapeutics, Inc.
Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.